Fulgent Genetics Valuation Multiples

Fulgent Genetics Overview

About Fulgent Genetics

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Founded

2016

HQ

Employees

1.3K

Website

fulgentgenetics.com

Sectors

Diagnostics & GenomicsLaboratory ServicesBioTechDeepTech

Financials (LTM)

Revenue: $330M

EBITDA: ($20M)

EV

$141M

Valuation Multiples

Multiples.vc

Start free trial

Fulgent Genetics Financials

Fulgent Genetics reported last 12-month revenue of $330M and negative EBITDA of ($20M).

In the same LTM period, Fulgent Genetics generated $132M in gross profit, ($20M) in EBITDA losses, and had net loss of ($70M).

Fulgent Genetics P&L

In the most recent fiscal year, Fulgent Genetics reported revenue of $323M and EBITDA of ($10M).

Fulgent Genetics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Fulgent Genetics Stock Performance

Fulgent Genetics has current market cap of $470M, and enterprise value of $141M.

Fulgent Genetics' stock price is $16.28.

Fulgent Genetics Valuation Multiples

Fulgent Genetics trades at 0.4x EV/Revenue multiple, and (7.0x) EV/EBITDA.

Fulgent Genetics Financial Valuation Multiples

As of April 20, 2026, Fulgent Genetics has market cap of $470M and EV of $141M.

Equity research analysts estimate Fulgent Genetics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Fulgent Genetics has a P/E ratio of (6.7x).

Fulgent Genetics Margins & Growth Rates

Fulgent Genetics' revenue in the last 12 month grew by 9%.

Fulgent Genetics' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.

Fulgent Genetics' rule of 40 is (4%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Fulgent Genetics' rule of X is 7% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Fulgent Genetics Public Comps

See public comps and valuation multiples for other Diagnostics & Genomics and Laboratory Services comps.

Fulgent Genetics M&A Activity

Fulgent Genetics acquired XXX companies to date.

Last acquisition by Fulgent Genetics was on XXXXXXXX, XXXXX. Fulgent Genetics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Fulgent Genetics Investment Activity

Fulgent Genetics invested in XXX companies to date.

Fulgent Genetics made its latest investment on XXXXXXXX, XXXXX. Fulgent Genetics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).